Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?The Motley Fool • 05/16/20
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Aimmune Therapeutics (AIMT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/11/20
Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut AllergiesSeeking Alpha • 05/06/20
One Call Still Sees a Double-Your-Money Upside from the Peanut Allergy Treatment24/7 Wall Street • 03/03/20
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/28/20
Is the Options Market Predicting a Spike in Aimmune (AIMT) Stock?Zacks Investment Research • 02/21/20
Aimmune Therapeutics (AIMT) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 02/12/20
Aimmune Proves Its Worth With Latest FDA Approval; Other Candidates Left To AdvanceSeeking Alpha • 02/11/20
Aimmune Analyst Says Palforzia Launch Funding Secured With Nestle's $200M InvestmentBenzinga • 02/06/20
Full Steam Ahead For Aimmune Therapeutics and the World's First Peanut Allergy TherapyThe Motley Fool • 02/05/20